STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.